Merck's Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy

Merck & Co., Inc. (NYSE:MRK) on Monday announced positive topline results from the Phase 3 HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH) functional class (FC) II or III at intermediate or high risk of disease progression.

HYPERION met its primary endpoint of time to clinical worsening (TTCW) as measured by a composite endpoint of all-cause death, the need for non-planned PAH-related hospitalization > 24 hours, atrial septostomy, lung transplantation, or PAH deterioration.

In HYPERION, Winrevair added on top of background therapy (72.2% of patients on double therapy) ...